Working… Menu

Myo-inositol Versus Metformin Administration in Post-menopausal Women With Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01046500
Recruitment Status : Unknown
Verified May 2014 by Rosario D'anna, University of Messina.
Recruitment status was:  Recruiting
First Posted : January 12, 2010
Last Update Posted : May 20, 2014
Information provided by (Responsible Party):
Rosario D'anna, University of Messina

Brief Summary:

Myo-Inositol is classified as a member of the vitamin B complex. It is a constituent of living cells and is widespread in many food. It is involved in a number of biological processes, including insulin signal transduction, resulting in modulating insulin sensitivity. One hundred post-menopausal women from 50 to 60 years old, affected by metabolic syndrome (criteria are described in NIH ATP III) will be randomized into two groups: 50 treated with myo-inositol 2 g twice per day and fifty treated with metformin for six months. Metformin is the drug usually used in diabetic and pre-diabetic conditions, as metabolic syndrome. The investigators hypothesize that the administration of myo-inositol would improve the insulin-receptor activity in these women, reducing insulin resistance as well as metformin.

OUTCOME MEASURE: HOMA-IR, blood pressure level, serum triglycerides and cholesterol, BMI and waist circumference

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Dietary Supplement: myo-inositol Drug: Metformin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2013
Estimated Primary Completion Date : June 2014
Estimated Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: metformin Drug: Metformin
pill, 250 mg, twice a day

Active Comparator: myo-inositol Dietary Supplement: myo-inositol
2 grams twice a day

Primary Outcome Measures :
  1. glycaemia, insulinaemia, HOMA-IR [ Time Frame: at baseline and after 6 months ]

Secondary Outcome Measures :
  1. serum triglycerides, HDL and total cholesterol, blood pressure level, BMI and waist circumference [ Time Frame: at baseline and after six months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-menopausal outpatients affected by the metabolic syndrome, whose criteria are described in NIH ATP III, 2001.

Exclusion Criteria:

  • Post-menopausal outpatients without metabolic syndrome
  • assumption of hypocholesterolemic or other insulin sensitizing drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01046500

Layout table for location information
University Hospital Recruiting
Messina, Italy
Contact: Rosario D'Anna, associate professor    +39 090 2217324   
Principal Investigator: Rosario D'Anna, associate professor         
Sponsors and Collaborators
University of Messina

Layout table for additonal information
Responsible Party: Rosario D'anna, Associate Professor, University of Messina Identifier: NCT01046500     History of Changes
Other Study ID Numbers: INOMEN-2010
First Posted: January 12, 2010    Key Record Dates
Last Update Posted: May 20, 2014
Last Verified: May 2014
Keywords provided by Rosario D'anna, University of Messina:
insulin resistance
body mass index
serum triglycerides and cholesterol
blood pressure
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances